Pyrazinamide

C. diff Risk

Low

Oral Bioavailability

Moderate

Approximate Cost

$

Dosing

Hepatic

  •  No dosage adjustments.

  •  Use is contraindicated in cases of severe hepatic impairment.

General Information

Common Usage

Active Tuberculosis treatment

Drug Monitoring

Laboratory

  •  CBC with diff and CMP at start and periodically during course

Clinical

  • Monitor for hepatotoxicity

Adverse Effects

  •  Malaise

  •  Anorexia

  •  Nausea

  •  Vomiting

  •  Arthralgia

  • Myalgia

  • Hepatotoxicity

Major Interactions

Cyclosporine, rifampin, multiple additional

Additional Information

Caution in:

  • Alcoholism

  • Diabetes

  • Gout

  • Porphyria

  • Renal impairment

Pharmacology

Metabolism: Hepatic